I-Mab changes corporate name to NovaBridge Biosciences

NovaBridge (NBP) Biosciences has changed its corporate name from I-Mab (IMAB) to NovaBridge Biosciences. The change was overwhelmingly approved by shareholders at the Company’s Extraordinary General Meeting held on October 24, 2025, and by the Company’s Board of Directors. The Company’s American Depositary Shares will trade on Nasdaq under the new name and a new ticker symbol, “NBP”, effective at the opening of trading on October 30, 2025, replacing its current symbol “IMAB”/ The new corporate brand, including a new website, marks an important step in the Company’s strategic transformation to a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide. In connection with the name change and ticker symbol change, no action is required from current shareholders and the Company’s CUSIP number will remain the same. Historical trading data of the Company’s ADSs prior to October 30, 2025 may not yet be available on certain third-party websites and apps when searching for “NovaBridge Biosciences” and/or “NBP”, in which case such data may temporarily be found under “I-MAB” and/or “IMAB”. The Company intends to partner with leading innovators to identify and accelerate high-value assets. Our model integrates rigorous asset selection, bespoke translational strategies, and efficient clinical execution. With the backing of CBC Group, we leverage deep local insights and global capabilities to develop the most promising drug candidates across a range of therapeutic categories. The Company will utilize a “hub-and-spoke” model to create and advance specialized subsidiary companies which maintain operational focus and agility. By focusing each spoke on a specific asset or therapeutic area, the Company can optimally manage risk and create value through potential partnering transactions.